A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07376642 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: IMV101 treatment

Sponsor

Suzhou Immunofoco Biotechnology Co., Ltd